Use of Baricitinib in Patients with Moderate and Severe COVID-19

https://academic.oup.com/cid/article-abstract/doi/10.1093/cid/ciaa879/5864596

In this retrospective cohort, 15 patients with moderate-severe COVID-19 were treated with baricitinib and hydroxychloroquine. Twelve of 15 recovered, and 3 died. We observed temporally associated clinical improvement following initiation of baricitinib in 11 of the 15 (73.3%) patients. This improvement was characterized by a normalization of body temperature, a decline in inflammatory markers and oxygen requirements, and recovery. Two of the 15 (13.3%) developed secondary bacterial or fungal infections during prolonged ICU stays. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.

Tags: ,